Senile dementia: treatment with deanol

Area of Science:

• Neuroscience
• Gerontology
• Pharmacology

Background:

• Cholinergic system dysfunction is implicated in memory deficits associated with senile dementia.
• Acetylcholine deficiency is a potential cause of cognitive impairment in aging populations.

Purpose of the Study:

• To evaluate the safety and efficacy of deanol (2-dimethylaminoethanol) in treating cognitive impairment in senile dementia patients.
• To determine if deanol administration can improve behavioral symptoms and cognitive function.

Main Methods:

• An open-label study involving 14 senile outpatients treated with deanol for 4 weeks.
• Dosage was escalated to 1800 mg/day, with safety monitored and cognitive function assessed using the Sandoz Clinical Assessment-Geriatric (SCAG) scale and cognitive tests.

Main Results:

• Deanol was well-tolerated with no adverse effects reported.
• Significant global improvement was observed in 10 patients (p < .01), with SCAG scores decreasing by week 3 (p < .01).
• Improvements were primarily noted in reduced depression, irritability, anxiety, and increased motivation, not in memory or other cognitive functions.

Conclusions:

• Deanol may offer behavioral benefits for some senile dementia patients, such as improved mood and motivation.
• The study suggests deanol does not improve memory or cognitive performance in this population.
• Observed behavioral changes are unlikely to be solely placebo effects, given comparisons to a separate study.